Katherine Stueland

Katherine Stueland, CEO of GeneDx and a dedicated patient advocate, shares her journey from raising funds for cystic fibrosis as a child to revolutionizing genomic testing. She highlights the innovative Infinity database that enhances diagnostic accuracy and the importance of newborn screening, revealing a 70% enrollment rate in their Guardian study with promising results. Katherine emphasizes empowering parents as advocates, her turnaround strategy at GeneDx, and the critical need for equitable genomic access for all families.

Katherine Stueland, President and CEO of GeneDx, discusses how AI is revolutionizing genetic testing to diagnose rare diseases in days instead of years. She highlights the evolution from single-gene testing to whole genome sequencing and the impact of a landmark Supreme Court decision on patient access. Katherine shares insights on the challenges parents face while navigating rare conditions and the critical role of genetic testing in NICUs. She also emphasizes the importance of women in leadership roles within healthcare.

Dan Greenhaus from Solus Alternative Asset Management, Courtney Garcia of Payne Capital Management, Brian Belski from BMO, Katherine Stueland, CEO of GeneDX, and Doug Clinton of Intelligent Alpha delve into the mega-cap tech landscape. They discuss the urgency surrounding Alphabet's upcoming earnings amid fierce competition and regulatory hurdles. Stueland also shares GeneDX's success in pediatric genetic diagnostics and their innovative approach to genetic testing. Insights into mid-cap investments and AI's impact on market dynamics provide listeners with valuable takeaways.